Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI3042 in Healthy, Overweight, or Obese Participants
NCT07802899Phase 1Not yet recruiting
- Sponsor
- Hongwei Jiang
- Start
- Sep 2026
- Primary completion
- Mar 2027
- Countries
- 1
01
Overview
Phase 1, randomised trial in obesity and Overweight comparing IBI3042 treatment Group with Placebo Control Group (2 arms). Primary endpoints: Number of Participants With Adverse Events at 57 days, Number of Participants With Abnormal Physical Examination Findings at 57 days and 3 more. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
IBI3042
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT07802899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07802899.